FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction

D. W. Wu, M. C. Lee, N. Y. Hsu, T. C. Wu, J. Y. Wu, Y. C. Wang, Y. W. Cheng, C. Y. Chen, H. Lee

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Fragile histidine triad (FHIT) loss by the two-hit mechanism of loss of heterozygosity and promoter hypermethylation commonly occurrs in non-small cell lung cancer (NSCLC) and may confer cisplatin resistance in NSCLC cells. However, the underlying mechanisms of FHIT loss in cisplatin resistance and the response to cisplatin-based chemotherapy in NSCLC patients have not yet been reported. In the present study, inhibition concentration of 50% cell viability induced by cisplatin (IC50) and soft agar growth and invasion capability were increased and decreased in FHIT-knockdown and -overexpressing cells, respectively. Mechanistically, Slug transcription is upregulated by AKT/NF-κB activation due to FHIT loss and, in turn, Slug suppresses PUMA expression; this decrease of PUMA by FHIT loss is responsible for cisplatin resistance. In addition, cisplatin resistance due to FHIT loss can be conquered by AKT inhibitor - perifosine in xenograft tumors. Among NSCLC patients, low FHIT, high p-AKT, high Slug and low PUMA were correlated with shorter overall survival, relapse-free survival and poorer response to cisplatin-based chemotherapy. Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome.

Original languageEnglish
Pages (from-to)2505-2515
Number of pages11
JournalOncogene
Volume34
Issue number19
DOIs
Publication statusPublished - May 7 2015

Fingerprint

Gastropoda
Histidine
Cisplatin
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Drug Therapy
Survival
Loss of Heterozygosity
Heterografts
Inhibitory Concentration 50
Agar
Neoplasms
Cell Survival
Recurrence
Growth

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics
  • Medicine(all)

Cite this

Wu, D. W., Lee, M. C., Hsu, N. Y., Wu, T. C., Wu, J. Y., Wang, Y. C., ... Lee, H. (2015). FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction. Oncogene, 34(19), 2505-2515. https://doi.org/10.1038/onc.2014.184

FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction. / Wu, D. W.; Lee, M. C.; Hsu, N. Y.; Wu, T. C.; Wu, J. Y.; Wang, Y. C.; Cheng, Y. W.; Chen, C. Y.; Lee, H.

In: Oncogene, Vol. 34, No. 19, 07.05.2015, p. 2505-2515.

Research output: Contribution to journalArticle

Wu, DW, Lee, MC, Hsu, NY, Wu, TC, Wu, JY, Wang, YC, Cheng, YW, Chen, CY & Lee, H 2015, 'FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction', Oncogene, vol. 34, no. 19, pp. 2505-2515. https://doi.org/10.1038/onc.2014.184
Wu, D. W. ; Lee, M. C. ; Hsu, N. Y. ; Wu, T. C. ; Wu, J. Y. ; Wang, Y. C. ; Cheng, Y. W. ; Chen, C. Y. ; Lee, H. / FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction. In: Oncogene. 2015 ; Vol. 34, No. 19. pp. 2505-2515.
@article{8c8cebab1833457aba22bd98064888f4,
title = "FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction",
abstract = "Fragile histidine triad (FHIT) loss by the two-hit mechanism of loss of heterozygosity and promoter hypermethylation commonly occurrs in non-small cell lung cancer (NSCLC) and may confer cisplatin resistance in NSCLC cells. However, the underlying mechanisms of FHIT loss in cisplatin resistance and the response to cisplatin-based chemotherapy in NSCLC patients have not yet been reported. In the present study, inhibition concentration of 50{\%} cell viability induced by cisplatin (IC50) and soft agar growth and invasion capability were increased and decreased in FHIT-knockdown and -overexpressing cells, respectively. Mechanistically, Slug transcription is upregulated by AKT/NF-κB activation due to FHIT loss and, in turn, Slug suppresses PUMA expression; this decrease of PUMA by FHIT loss is responsible for cisplatin resistance. In addition, cisplatin resistance due to FHIT loss can be conquered by AKT inhibitor - perifosine in xenograft tumors. Among NSCLC patients, low FHIT, high p-AKT, high Slug and low PUMA were correlated with shorter overall survival, relapse-free survival and poorer response to cisplatin-based chemotherapy. Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome.",
author = "Wu, {D. W.} and Lee, {M. C.} and Hsu, {N. Y.} and Wu, {T. C.} and Wu, {J. Y.} and Wang, {Y. C.} and Cheng, {Y. W.} and Chen, {C. Y.} and H. Lee",
year = "2015",
month = "5",
day = "7",
doi = "10.1038/onc.2014.184",
language = "English",
volume = "34",
pages = "2505--2515",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "19",

}

TY - JOUR

T1 - FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction

AU - Wu, D. W.

AU - Lee, M. C.

AU - Hsu, N. Y.

AU - Wu, T. C.

AU - Wu, J. Y.

AU - Wang, Y. C.

AU - Cheng, Y. W.

AU - Chen, C. Y.

AU - Lee, H.

PY - 2015/5/7

Y1 - 2015/5/7

N2 - Fragile histidine triad (FHIT) loss by the two-hit mechanism of loss of heterozygosity and promoter hypermethylation commonly occurrs in non-small cell lung cancer (NSCLC) and may confer cisplatin resistance in NSCLC cells. However, the underlying mechanisms of FHIT loss in cisplatin resistance and the response to cisplatin-based chemotherapy in NSCLC patients have not yet been reported. In the present study, inhibition concentration of 50% cell viability induced by cisplatin (IC50) and soft agar growth and invasion capability were increased and decreased in FHIT-knockdown and -overexpressing cells, respectively. Mechanistically, Slug transcription is upregulated by AKT/NF-κB activation due to FHIT loss and, in turn, Slug suppresses PUMA expression; this decrease of PUMA by FHIT loss is responsible for cisplatin resistance. In addition, cisplatin resistance due to FHIT loss can be conquered by AKT inhibitor - perifosine in xenograft tumors. Among NSCLC patients, low FHIT, high p-AKT, high Slug and low PUMA were correlated with shorter overall survival, relapse-free survival and poorer response to cisplatin-based chemotherapy. Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome.

AB - Fragile histidine triad (FHIT) loss by the two-hit mechanism of loss of heterozygosity and promoter hypermethylation commonly occurrs in non-small cell lung cancer (NSCLC) and may confer cisplatin resistance in NSCLC cells. However, the underlying mechanisms of FHIT loss in cisplatin resistance and the response to cisplatin-based chemotherapy in NSCLC patients have not yet been reported. In the present study, inhibition concentration of 50% cell viability induced by cisplatin (IC50) and soft agar growth and invasion capability were increased and decreased in FHIT-knockdown and -overexpressing cells, respectively. Mechanistically, Slug transcription is upregulated by AKT/NF-κB activation due to FHIT loss and, in turn, Slug suppresses PUMA expression; this decrease of PUMA by FHIT loss is responsible for cisplatin resistance. In addition, cisplatin resistance due to FHIT loss can be conquered by AKT inhibitor - perifosine in xenograft tumors. Among NSCLC patients, low FHIT, high p-AKT, high Slug and low PUMA were correlated with shorter overall survival, relapse-free survival and poorer response to cisplatin-based chemotherapy. Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome.

UR - http://www.scopus.com/inward/record.url?scp=84938089515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938089515&partnerID=8YFLogxK

U2 - 10.1038/onc.2014.184

DO - 10.1038/onc.2014.184

M3 - Article

C2 - 24998847

AN - SCOPUS:84938089515

VL - 34

SP - 2505

EP - 2515

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 19

ER -